trial · primary record
Antigen-specific T cells CART/CTL and DCvac
Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2026-07-31 |
| Primary endpoint | Percentage of adverse effects after CART/CTL/DCvac cells injection |
| Registry ID | NCT04085159 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:52.882Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04085159
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Antigen-specific T cells CART/CTL and DCvac · compound